Multiple sclerosis risk sharing scheme: Two year results of clinical cohort study with historical comparator

BMJ (Online)

Volumn 339, Issue 7734, 2009, Pages 1359-1363

  Boggild, Mike ^a   Palace, Jackie ^b   Barton, Pelham ^c   Ben Shlomo, Yoav ^d   Bregenzer, Thomas ^e   Dobson, Charles ^d   Gray, Richard ^c  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Canynge Hall ^*  (United Kingdom)

^e PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; REMISSION; UNITED KINGDOM;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS;

EID: 72449125358     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b4677     Document Type: Article

References (21)

1. National Institute for Health and Clinical Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE, 2002 (Technology Appraisal Guidance No 32).
2. Chilcott J, McCabe C, Tappenden P, Cooper NJ, Abrams K, Claxton K. Modelling the cost-effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003;326:522-526 (Pubitemid 36321743)
3. Hemmett L, Holmes J, Barnes M, Russell N.What drives quality of life in multiple sclerosis? QJM 2004;97:671-676
4. Kobelt G, Lindgren P, Parkin D, Francis DA, Johnson M, Bates D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the UK. Scandinavian Working Papers in Economics, 2000 (http://swopec.hhs.se/hastef/papers/hastef0398.pdf).
5. Ebers G. Natural history of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, McDonald IR, Matthews B, Wekerle H. McAlpine's multiple sclerosis. 3rd ed. Churchill Livingstone, 1998.
6. Association of British Neurologists. Guidelines for treatment with interferon beta and glatiramer acetate in multiple sclerosis. ABN, 2001. www.theabn.org/documents/msdoc.pdf.
7. Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. Health Service Circular, 2002/004 (latest update October 2006). www.dh.gov.uk/en/PublicationsAndStatistics/ LettersAndCirculars/HealthServiceCirculars/DH-4004332.
8. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983;33:1444-1452
9. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis F, Ebers GE, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231 (Pubitemid 13158528)
10. Rice G, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;(4):CD002002.
11. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;24:172-177 (Pubitemid 43970148)
12. Sudlow CLM, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003;326:388-392 (Pubitemid 36241480)
13. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive ofmultiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397
14. Lechner-Scott J, Kappos L, Hofman M, Polman C, Ronner H, Montalblan X, et al. Can the expanded disability status scale be assessed by telephone? Multiple Sclerosis 2003;9:154-159
15. Association of British Neurologists. Guidelines for treatment of multiple sclerosis with interferon beta and glatiramer acetate. ABN, 2007.
16. Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-termeffectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366:378-384
17. Department of Health/ABPI. The 2009 pharmaceutical price regulation scheme. www.dh.gov.uk/en/Publicationsandstatistics/Publications/DH-091825.
18. Chapman S, Reeve E, Rajaratnam G, Neary R. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ 2003;326:707-709 (Pubitemid 36390459)
19. National Institute for Health and Clinical Excellence. Bortezomib monotherapy for relapsed multiple myeloma. NICE, 2007 (Technology Appraisal Guidance No 129).
20. Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Tech Ass Health Care 2007;23:425-435 (Pubitemid 47586920)
21. NINDS NET-PD Investigators. A randomised, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671